Netflix, Inc. (Nasdaq: NFLX) has unveiled revealing, new information that confirms a sneaking suspicion— more than half (51%) of couples are likely to “cheat”1—but don’t start grilling your significant other or giving them the evil eye just yet.
A recent survey conducted by Harris Interactive on behalf of Netflix2 revealed 51% of those in a relationship would “cheat” on their spouse/partner/significant other by streaming a TV program(s) they agreed to watch together before their partner had a chance to watch it. More specifically, more than 28 million3 U.S. adults (12%) confessed they had already cheated and 10% admitted they had been “cheated on4.” It seems as though sometimes that next episode of your favorite series is just too tempting to wait for your partner. Sneaking around with that addictive little show may seem like a minor form of infidelity—but don’t be surprised if it leads to a few slamming doors and a bit of the silent treatment.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61735-netflix-survey-more-than-half-of-couples-consider-stream-cheating
Overstock.com, Inc. (NASDAQ: OSTK) released the first commercial in their new series starring NFL Coach and Hall of Famer Mike Ditka and quarterback Jim McMahon.
\
In recognition of Melanoma Monday® and National Melanoma/Skin Cancer Detection & Prevention MonthTM, MELA Sciences, Inc. (NASDAQ: MELA) visited the NASDAQ MarketSite in Times Square today to ring the Opening Bell and sponsor free skin cancer checks.
One American dies every hour from melanoma, the most deadly skin cancer. MELA Sciences, Inc. is the pioneer company behind MelaFind®, the first and only FDA-approved diagnostic tool that helps dermatologists detect melanoma at its most curable stage. MelaFind® was approved by the U.S. Food & Drug Administration (FDA) in Fall 2011, and since then has strategically rolled out the technology to dermatology practices across the country.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61584-mela-sciences-rings-opening-bell-awareness-melanoma-detection-prevention
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management solutions, today announced Accelrys Insight and Accelrys Insight for Excel, completing the roll-out of Accelrys’ next-generation cheminformatics suite and providing an interactive, collaborative environment for rapid and effective decision-making in drug discovery. Accelrys Insight and Accelrys Insight for Excel offer research scientists an entirely new way of accessing, visualizing and analyzing data that is locked in disparate locations across internal discovery teams and networked external partners, helping to lower long-standing barriers to bringing innovative therapeutics to market faster and more cost effectively.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62191-accelrys-insight-next-generation-decision-making-in-scientific-discovery
Marvell (NASDAQ: MRVL), a worldwide leader in integrated silicon solutions, this week demonstrated its AVANTA™ family of optical broadband access solutions for the entertainment industry in Hollywood. AVANTA is designed to accelerate the quality and speed of internet connectivity in the home — 100 times the bandwidth and speed of current offerings—enabling superior levels of rich media delivery to all consumers.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/marvell/43476/
Marriott International Inc., (NASDAQ: MAR) is encouraging travelers and shareholders to “Find their World” through the company’s interactive 2013 Annual Report. Designed with modern social media platforms as inspiration, the interactive report uses captivating images of some of Marriott’s hotels in more than 70 countries across the globe to guide readers through the company’s major achievements and innovations of 2013, including mobile check-in, the announcement of Moxy® hotels and the acquisition of African hotel chain Protea.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7107851-marriott-international-find-your-world-interactive-2013-annual-report
LivePerson, Inc. (NASDAQ: LPSN), a provider of real-time chat, voice and content solutions that increase conversions and improve customer experience, today announced several new innovations in online engagement. These new capabilities enhance the intelligence, extend the reach, and improve the efficiency of online chat.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54324-liveperson-lp-chat-latest-innovations-in-online-engagement
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management solutions, has announced the availability of an extensive set of advanced predictive sciences applications and services. These integrated capabilities enable drug discovery teams to investigate and evaluate hypotheses about the chemical or biological behavior of molecules of therapeutic interest in silico prior to costly experimentation. Accelrys predictive sciences leverages the open, scientifically aware Accelrys Enterprise Platform to deliver an advanced scientific decision support environment that reduces time and expense, improves quality, enhances collaboration and accelerates innovation in bringing new drugs to market.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62190-accelrys-offers-integrated-predictive-sciences-solutions-faster-innovation
Jive Software, Inc. (Nasdaq:JIVE), rolled out today the latest version of Producteev by Jive, the leading social task management solution that allows individuals, teams, and now entire organizations to easily track and manage tasks for free – regardless of how many people within a team or organization use the application and an approach that no other task management app on the market can match today. The new version of the product builds on the innovative foundation built by Producteev, which was acquired by Jive late last year, and provides companies with a more productive yet inexpensive way to get the fundamental components of work — tasks — organized and completed easily.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61749-jive-software-producteev-task-management-more-conceptual-and-organized
LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today recognizes that more than one million people in the United States with drug-resistant epilepsy continue to be treated unsuccessfully with drugs, despite the proven effectiveness of non-drug treatment options. LivaNova’s VNS Therapy®, for example, is a medical device treatment specifically designed for people with drug-resistant epilepsy that is already used by more than 85,000 people around the world.
One in three people with epilepsy has the type that is not well controlled with drugs, called drug-resistant epilepsy. For those people, prescribing more medicine is usually not the most effective option. In fact, research shows that if you haven’t found seizure freedom after your first two drugs, there is a 95 percent chance that no drug or combination of drugs will result in seizure freedom.
“Despite what we know about drug-resistant epilepsy, the majority of people affected by this condition will continue to be prescribed additional medications instead of being evaluated for surgery or seen in a specialized epilepsy facility,” said Jason Richey, president of LivaNova’s U.S. Region and general manager of the Neuromodulation Business Franchise. “This treatment gap means over one million individuals in the U.S. with undertreated epilepsy remain at risk for dangerous side effects of continued seizures, including injury, depression, memory issues and death.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7966451-livanova-vns-therapy-epilepsy/
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from two Phase 2 trials with SAR236553/REGN727, an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), were presented at the American College of Cardiology’s (ACC) 61st Annual Scientific Meeting in Chicago.
The data showed that treatment with SAR236553/REGN727 over 8 to 12 weeks significantly reduced mean low-density lipoprotein-cholesterol (LDL-C, or “bad” cholesterol) by 40% to 72% in patients with elevated LDL-C on stable dose of statins.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55299-sanofi-regeneron-pharmaceuticals-lipid-lowering-medications-pcsk9-antibody
Isle of Capri Casinos, Inc. (NASDAQ: ISLE) and Nemacolin Woodlands Resort announced today that Lady Luck Casino Nemacolin opened to the public at noon today to enthusiastic crowds. Lady Luck Casino Nemacolin, which is located approximately 70 miles south of Pittsburgh, created over 350 construction jobs, received approximately 2500 job applications and hired over 500 employees.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62069-isle-of-capri-casinos-lady-luck-casino-nemacolin-opens
